Francesca Nuti

Dr. Francesca Nuti

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in ASN Neuro
Verified
Journal Article
Open access
CTChiara Testa
Chiara Testa
FNFrancesca Nuti
Francesca Nuti
JHJoussef Hayek
Joussef Hayek
CFClaudio De Felice
Claudio De Felice
MCMario Chelli
Mario Chelli
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini
ASDs (autism spectrum disorders) are a complex group of neurodevelopment disorders, still poorly understood, steadily rising in frequency and treatment refracto...

12 July 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FLFrancesco Lolli
Francesco Lolli
BMBarbara Mulinacci
Barbara Mulinacci
ACAlfonso Carotenuto
Alfonso Carotenuto
Bruno BonettiBruno Bonetti
Bruno Bonetti
GSGiuseppina Sabatino
Giuseppina Sabatino
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini
Multiple sclerosis (MS) is a complex disease that seems to depend on several pathophysiological processes. Because of its varied clinical presentation, natural history, and response to therapeutic interventions, MS can be considered to be a group of diseases that have not been yet characterized, thus resulting in difficult evaluation of prognosis. In the last few years, the role of autoAbs in MS has been reevaluated, and, therefore, their identification as specific biomarkers became a relevant target. In this paper, we demonstrate that an aberrant N-glucosylation is a fundamental determinant of autoAb recognition in MS. Thus, we developed CSF114(Glc), an antigenic probe accurately measuring IgM autoAbs in the sera of a patient population, as disease biomarker. The relevance of CSF114(Glc) is demonstrated by its clinical application and correlation with disease activity and prognosis. In fact, CSF114(Glc), a structure-based designed glycopeptide, is able to recognize, by ELISA, the presence of specific IgM autoAbs in the sera of a MS patient population but not in blood donors and other autoimmune conditions. AutoAbs specific for CSF114(Glc) isolated from MS patients recognized myelin and oligodendrocyte antigens by immunohistochemistry but not other nonrelevant tissues. We demonstrate that CSF114(Glc) is a reliable, specific probe in a longitudinal study of untreated MS patients. Development of IgG/IgM anti-CSF114(Glc) Abs paralleled clinical activity and brain lesions positive to MRI. Therefore, a CSF114(Glc)-based immunoassay on sera may have important prognostic value in monitoring MS disease progression guiding optimal therapeutic treatment.

23 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASArianna Smerieri
Arianna Smerieri
CTChiara Testa
Chiara Testa
PLPietro Lazzeroni
Pietro Lazzeroni
FNFrancesca Nuti
Francesca Nuti
EGEnzo Grossi
Enzo Grossi
Maria E StreetMaria E Street
Maria E Street
Phthalates might be implicated with obesity and insulin sensitivity. We evaluated the levels of primary and secondary metabolites of Di-(2-ethylhexyl) phthalate (DEHP) in urine in obese and normal-weight subjects both before and during puberty, and investigated their relationships with auxological parameters and indexes of insulin sensitivity. DEHP metabolites (MEHP, 6-OH-MEHP, 5-oxo-MEHP, 5-OH-MEHP, and 5-CX-MEHP), were measured in urine by RP-HPLC-ESI-MS. Traditional statistical analysis and a data mining analysis using the Auto-CM analysis were able to offer an insight into the complex biological connections between the studied variables. The data showed changes in DEHP metabolites in urine related with obesity, puberty, and presence of insulin resistance. Changes in urine metabolites were related with age, height and weight, waist circumference and waist to height ratio, thus to fat distribution. In addition, clear relationships in both obese and normal-weight subjects were detected among MEHP, its products of oxidation and measurements of insulin sensitivity. It remains to be elucidated whether exposure to phthalates per se is actually the risk factor or if the ability of the body to metabolize phthalates is actually the key point. Further studies that span from conception to elderly subjects besides further understanding of DEHP metabolism are warranted to clarify these aspects.

28 June 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VVVictor V. Volkov
Victor V. Volkov
FNFrancesca Nuti
Francesca Nuti
YTYuji Takaoka
Yuji Takaoka
Riccardo ChelliRiccardo Chelli
Riccardo Chelli
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini
RRRoberto Righini
Roberto Righini

1 April 2007 in Tetrahedron Letters
Verified
Journal Article
Closed access
IPIlaria Paolini
Ilaria Paolini
FNFrancesca Nuti
Francesca Nuti
MPMaria de la Cruz Pozo-Carrero
Maria de la Cruz Pozo-Carrero
FBFrancesca Barbetti
Francesca Barbetti
BKBeata Kolesinska
Beata Kolesinska
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini

1 January 2008 in Peptide Science
Verified
Journal Article
Closed access
PDF file
FFFeliciana Real Fernández
Feliciana Real Fernández
ACAmélie Colson
Amélie Colson
JBJérome Bayardon
Jérome Bayardon
FNFrancesca Nuti
Francesca Nuti
EPElisa Peroni
Elisa Peroni
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini